{"id":390,"date":"2026-01-26T14:46:31","date_gmt":"2026-01-26T13:46:31","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/26\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/"},"modified":"2026-02-03T11:01:12","modified_gmt":"2026-02-03T10:01:12","slug":"crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/","title":{"rendered":"Crohn&#8217;s disease: Study on the efficacy and safety of risankizumab (FORTIFY)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Listings&#8221; module_id=&#8221;target group&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;custom&#8221; background_image_width=&#8221;90%&#8221; background_position=&#8221;bottom_right&#8221; top_divider_height=&#8221;51px&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;3&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|auto|-1px|auto|false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_post_title meta=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#10344C&#8221; title_font_size=&#8221;45px&#8221; custom_margin=&#8221;||15px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_post_title][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;1f09816e-184e-4ce5-a4cf-b39c52c423ca&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#10344C&#8221; text_font_size=&#8221;20px&#8221; text_line_height=&#8221;1.8em&#8221; ul_line_height=&#8221;1.8em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; text_font_size_tablet=&#8221;15px&#8221; text_font_size_phone=&#8221;14px&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; header_font_size_tablet=&#8221;55px&#8221; header_font_size_last_edited=&#8221;off|desktop&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>ClinicalTrials.gov ID:<\/strong> NCT03105102<br \/><strong>Sponsor:<\/strong> AbbVie<\/p>\n<p><strong>Official title:<\/strong><br \/>A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with Crohn&#8217;s disease.<\/p>\n<p><strong>Study overview:<\/strong><br \/>The study consists of four sub-studies:<\/p>\n<ul>\n<li>Sub-study 1: Randomized, double-blind, placebo-controlled maintenance study in patients who have responded to intravenous risankizumab induction<\/li>\n<li>Sub-study 2: Randomized, exploratory study with two dosage regimens<\/li>\n<li>Sub-study 3: Open-label long-term extension study to investigate long-term safety, efficacy and tolerability<\/li>\n<li>Sub-study 4: Open-label study with On-Body-Injector (OBI) to evaluate patient-reported outcomes, efficacy, safety, tolerability and pharmacokinetics<\/li>\n<\/ul>\n<p>In addition, an open-label continuous treatment extension (OL CTE) to ensure an uninterrupted supply until risankizumab is commercially available.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ClinicalTrials.gov ID: NCT03105102Sponsor: AbbVie Official title:A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with Crohn&#8217;s disease. Study overview:The study consists of four sub-studies: Sub-study 1: Randomized, double-blind, placebo-controlled maintenance study in patients who have responded to intravenous risankizumab induction Sub-study 2: [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-390","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crohn&#039;s disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crohn&#039;s disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:46:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:01:12+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Crohn&#8217;s disease: Study on the efficacy and safety of risankizumab (FORTIFY)\",\"datePublished\":\"2026-01-26T13:46:31+00:00\",\"dateModified\":\"2026-02-03T10:01:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/\"},\"wordCount\":333,\"articleSection\":[\"Active, recruitment completed\",\"For study partners\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/\",\"name\":\"Crohn's disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\"},\"datePublished\":\"2026-01-26T13:46:31+00:00\",\"dateModified\":\"2026-02-03T10:01:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ced-study-center-karlshorst\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crohn&#8217;s disease: Study on the efficacy and safety of risankizumab (FORTIFY)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/author\\\/paulilauterbachnutzer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crohn's disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/","og_locale":"en_US","og_type":"article","og_title":"Crohn's disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst","og_description":"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-26T13:46:31+00:00","article_modified_time":"2026-02-03T10:01:12+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Crohn&#8217;s disease: Study on the efficacy and safety of risankizumab (FORTIFY)","datePublished":"2026-01-26T13:46:31+00:00","dateModified":"2026-02-03T10:01:12+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/"},"wordCount":333,"articleSection":["Active, recruitment completed","For study partners"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/","name":"Crohn's disease: Study on the efficacy and safety of risankizumab (FORTIFY) - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-26T13:46:31+00:00","dateModified":"2026-02-03T10:01:12+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Crohn&#8217;s disease: Study on the efficacy and safety of risankizumab (FORTIFY)"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=390"}],"version-history":[{"count":3,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/390\/revisions"}],"predecessor-version":[{"id":395,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/390\/revisions\/395"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}